OKUR
OnKure Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.95
−0.34%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$2.96
From 52W high−44.02%
Volume223090.00
Market cap$119.46M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$2.96
From 52W high
−44.02%
Volume
223090.00
Market cap
$119.46M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
1.0x
P/E (TTM)
—
RSI (14)
25.9
MomentumView details →
1D Return
−0.34%
YTD Return
+3.45%
SummaryUpdated Jun 1, 2026
OnKure Therapeutics, Inc. (NASDAQ:OKUR) is a clinical-stage biotechnology company founded in 2011 and headquartered in Boulder, Colorado. The company specializes in discovering and developing precision oncology medicines, with a particular focus on creating selective inhibitors of histone deacetylases (HDACs) for treating various forms of cancer. OnKure went public through a merger transaction and currently trades on NASDAQ, representing one of the smaller players in the competitive oncology drug development space.
Similar companies
Latest newsMore news →
OnKure Therapeutics repriced outstanding stock options for its CEO, CMO, and CFO to $4.14 per share, effective August 7, 2026, subject to an 18-month retention requirement.39d agoOnKure Therapeutics, Inc. elected R. Michael Carruthers, Valerie M. Jansen, M.D., Ph.D., and Edward T. Mathers as Class II directors, effective June 3, 2026.109d ago